The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Key considerations in the management of oligometastatic GI cancers
Nataliya Uboha, MD, PhD, University of Wisconsin Carbone Cancer Center, Madison, WI, addresses key considerations in managing oligometastatic gastrointestinal (GI) cancers. She emphasizes the need for data, highlighting ongoing prospective randomized studies to better understand the role of oligometastatic disease. Dr Uboha underscores the significance of tumor biology, including metastasis site, molecular characteristics, and patients’ treatment history. Notably, she mentions large phase three studies in progress, both in Europe and the United States, aiming to determine optimal approaches for oligometastatic GI cancers. In the U.S., she chairs a Phase III trial, ECOG-ACRIN EA2183 (NCT04248452), investigating the role of consolidated radiation therapy in patients with oligometastatic upper GI cancers. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
